Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00424398 · ClinicalTrials.gov registry record · Phase 2
Evaluation of the Onset and Duration of Action of Bepotastine Besilate Ophthalmic Solution in Acute Allergic Conjunctivitis
A Phase 2 study of Conjunctivitis, Allergic, sponsored by Bausch & Lomb Incorporated.
- Completed
- Registry status
- Phase 2
- Development phase
- 107
- Enrollment target
- 1
- Study location
NCT00424398: Completed Phase 2 study of Conjunctivitis, Allergic, sponsored by Bausch & Lomb Incorporated.
NCT00424398 is a Phase 2 study of Conjunctivitis, Allergic that has completed, run by Bausch & Lomb Incorporated. The registered enrollment target is 107 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (20% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00424398, a Phase 2 study of Conjunctivitis, Allergic, has completed, sponsored by Bausch & Lomb Incorporated.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 107 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to evaluate whether bepotastine besilate ophthalmic solution is effective in the treatment of acute allergic conjunctivitis
Primary Outcome
Ocular Itching score: 0=None; 0.5=Intermittent tickle sensation possibly localized in the corner of the eye; 1.0=Intermittent tickle sensation involving more than the corner of the eye; 1.5=Intermittent all-over tickling sensation; 2.0=Mild continuous itch (can be localized) without desire to rub; 2.5=Moderate, diffuse continuous itch with desire to rub; 3.0=Severe itch with desire to rub; 3.5=Severe itch improved with minimal rubbing; 4.0=Incapacitating itch with irresistible urge to rub
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Bepreve
- DRUG Bepotastine Besilate
Study Locations (1)
California
- ISTA Pharmaceuticals, Inc. - Irvine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 107 participants |
| Start Date | 2007-02 |
| Phase | Phase 2 |
What the finished NCT00424398 record still lists
NCT00424398 is an interventional study that assigns participants to a tested intervention. The registered 107 participants enrollment target is mid-sized for trials with a published cap, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (20% lower).
The record links to 1 condition, with Conjunctivitis, Allergic appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT00424398 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT00424398 about?
NCT00424398 is a clinical study titled "Evaluation of the Onset and Duration of Action of Bepotastine Besilate Ophthalmic Solution in Acute Allergic Conjunctivitis". The purpose of this study is to evaluate whether bepotastine besilate ophthalmic solution is effective in the treatment of acute allergic conjunctivitis
What is the current status of trial NCT00424398?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 107 participants. The study started on 2007-02.
What conditions does trial NCT00424398 study?
This clinical trial studies the following conditions: Conjunctivitis, Allergic.
What interventions are being tested in trial NCT00424398?
The interventions under investigation include: Placebo (DRUG), Bepreve (DRUG), Bepotastine Besilate (DRUG).
Who is sponsoring clinical trial NCT00424398?
This trial is sponsored by Bausch & Lomb Incorporated, which has 174 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00424398 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00424398's enrollment target sits among peer trials
107 646th of 2000 higher than 1,353 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05491668 · 107 participants
Physiological Assessment of Severe Coronary Stenosis for Informing Planned PCI
- NCT06041594 · 107 participants · NA
Treating Pulmonary Embolism With Laguna Thrombectomy System (TRUST)
- NCT06081426 · 107 participants · NA
Examining Neurobiological Mechanisms Underlying the Therapeutic Effect of the Ketogenic Diet in Bipolar Disorder (BD)
- NCT06527599 · 107 participants · NA
Screening in Trauma for Opioid Misuse Prevention - an Adaptive Intervention
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia